TITLE:
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD

CONDITION:
Acute Graft Versus Host Disease

INTERVENTION:
pentostatin for injection

SUMMARY:

      To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to
      identify the minimal effective dose of pentostatin defined as the lowest dose that produces
      a response in 20% or more of patients while producing treatment failure (defines as death,
      grade 3/4 toxicity, or progressive disease) in 40% or less of patients.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 6 Months to N/A
Criteria:

        Inclusion:

          -  Patients 6 months of age with grade 2 GVHD that is steroid-refractory

          -  Must be engrafted with ANC 1000/mL, may still be transfusion dependent for platelets
             and PRBC

          -  Time post stem cell infusion < 100 days

          -  Written informed consent

          -  Must have adequate renal function (creatinine clearance 40 mL/min/1.73 m2

        Exclusion:

          -  Post-transplant lymphoproliferative disease

          -  Uncontrolled infection

          -  Mental illness or other condition preventing full cooperation with the treatment and
             monitoring requirements of the study

          -  ATG within the previous 14 days

          -  Other immunosuppressive agents (including monoclonal antibodies) when initiated
             within the previous 7 days.
      
